Inventor · disambiguated record
Valerjans Kauss
Also filed as: KAUSS VALERJANS
12 granted patents·12 pending applications·339 citations·filing 1998–2011
89Inventor score
Top patents by PatentIndex Score
24 records- 0196US6034134A1-Amino-alkylcyclohexane NMDA receptor antagonistsMERZ & CO GMBH & CO·Filed 1998·Granted Mar 7, 2000·238 cites·22 claims
- 0284US6071966A1-amino-alkylcyclohexane NMDA receptor antagonistsMERZ & CO GMBH & CO·Filed 1998·Granted Jun 6, 2000·74 cites·12 claims
- 0380US7985753B2Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulatorsMERZ PHARMA GMBH & CO KGAA·Filed 2007·Granted Jul 26, 2011·6 cites·19 claims
- 0478US6828462B2Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonistsMERZ PHARMA GMBH & CO KGAA·Filed 2002·Granted Dec 7, 2004·14 cites·9 claims
- 0569US7947689B2Substituted pyrazolo[1,5-a]pyrimidines as metabotropic glutamate receptor modulatorsMERZ PHARMA GMBH & CO KGAA·Filed 2007·Granted May 24, 2011·1 cites·19 claims
- 0667US7598384B2Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptorsMERZ PHARMA GMBH & CO KGAA·Filed 2005·Granted Oct 6, 2009·1 cites·77 claims
- 0766US6602862B11-Amino-alkylcyclohexanes as trypanocidal agentsMERZ PHARMA GMBH & CO KGAA·Filed 2000·Granted Aug 5, 2003·3 cites·16 claims
- 0862US7022729B2Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonistsMERZ PHARMA GMBH & CO KGAA·Filed 2003·Granted Apr 4, 2006·1 cites·3 claims
- 0961US2009227582A1Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptorsMERZ PHARMA GMBH & CO KGAA·Filed 2009·Application pending·0 cites
- 1057US8288549B2Glycine B antagonistHENRICH MARKUS·Filed 2009·Granted Oct 16, 2012·1 cites·12 claims
- 1156US2007185151A1Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3 and neuronal nicotinic receptor antagonistsMERZ PHARMA GMBH & CO KGAA·Filed 2007·Application pending·0 cites
- 1255US7238703B2Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonistsMERZ PHARMA GMBH & CO KGAA·Filed 2005·Granted Jul 3, 2007·0 cites·3 claims
- 1353US7550482B2Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptorsMERZ PHARMA GMBH & CO KGAA·Filed 2005·Granted Jun 23, 2009·0 cites·11 claims
- 1453US2007105961A11-Amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonistsMERZ PHARMA GMBH & CO KGAA·Filed 2006·Application pending·0 cites
- 1548US2011003820A1Pyrazolopyrimidines, a process for their preparation and their use as medicineMERZ PHARMA GMBH & CO KGAA·Filed 2009·Application pending·0 cites
- 1647US2011212956A1Pyrazolopyrimidines for treating CNS disordersMERZ PHARMA GMBH & CO KGAA·Filed 2011·Application pending·0 cites
- 1745US2007299113A1Metabotropic glutamate receptor modulatorsMERZ PHARMA GMBH & CO KGAA·Filed 2007·Application pending·0 cites
- 1843US2010298442A11-Amino-alkyl-cyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonistsMERZ PHARMA GMBH & CO KGAA·Filed 2010·Application pending·0 cites
- 1942US2006004001A1Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptorsMERZ PHARMA GMBH & CO KGAA·Filed 2005·Application pending·0 cites
- 2040US8692021B2Method of preparing Neramexane or a salt thereofGOLD MARKUS-RENE·Filed 2010·Granted Apr 8, 2014·0 cites·18 claims
- 2138US2006074083A1Cyclic and acyclic propenones for treating CNS disordersMERZ PHARMA GMBH & CO KGAA·Filed 2005·Application pending·0 cites
- 2235US2003195212A1Novel melanocortin receptor agonists and antagonistsFiled 2001·Application pending·0 cites
- 2327US2012178742A1Metabotropic glutamate receptor modulatorsHENRICH MARKUS·Filed 2010·Application pending·0 cites
- 2424US2012220577A1Glycine b antagonistsHENRICH MARKUS·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Valerjans Kauss files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →